Genetics, genomics, and proteomics: Implications for the diagnosis and the treatment of chronic hepatitis C

Seminars in Liver Disease

Volumn 27, Issue 1, 2007, Pages 13-27

  Asselah, Tarik ^a   Bièche, Iwan ^b   Paradis, Valérie ^c   Bedossa, Pierre ^c   Vidaud, Michel ^b   Marcellin, Patrick ^a,c  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b INSERM   (France)

^c BEAUJON HOSPITAL   (France)

Author keywords

Fibrosis progression; HLA loci; Microarray; Pegylated interferon; Prediction

Indexed keywords

ANTIVIRUS AGENT; BLOOD CLOTTING FACTOR; CHEMOKINE RECEPTOR CCR5; CYTOKINE; HFE PROTEIN; HLA ANTIGEN; INTERFERON; PEGINTERFERON; RIBAVIRIN;

DISEASE COURSE; DISEASE SEVERITY; DNA MICROARRAY; DRUG WITHDRAWAL; GENE EXPRESSION; GENE LOCUS; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; GENOMICS; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HUMAN; LIVER FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REPLICON; REVIEW; RISK FACTOR; SEQUENCE ANALYSIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIVIRAL AGENTS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENOMICS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEOMICS; RECEPTORS, CCR5;

EID: 33847054368     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-960168     Document Type: Review

References (132)

1. Choo QL, Kuo G, Werner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362
2. Lanford RE, Bigger C, Bassett S, Klimpel G. The chimpanzee model of hepatitis C virus infections. ILAR J 2001;42:117-126
3. Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113
4. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000;290: 1972-1974
5. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796
6. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102:9294-9299
7. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309:623-626
8. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-945
9. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003;300:1145-1148
10. Tan SL, Nakao H, He Y, et al. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA 1999;96:5533-5538
11. Ghosh AK, Majumder M, Steele R, et al. Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP. J Biol Chem 2000; 275:7184-7188
12. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001;98:9599-9604
13. Polyak SJ, Khabar KS, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001;75:6095-6106
14. Girard S, Shalhoub P, Lescure P, et al. An altered cellular response to Interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology 2002;295:272-283
15. Ghosh AK, Majumder M, Steele R, et al. Modulation of Interferon expression by hepatitis C virus NS5A protein and human homeodomain protein PTX1. Virology 2003; 306:51-59
16. Girard S, Vossman E, Misek DE, et al. Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses. Hepatology 2004;40:708-718
17. Geiss GK, Carter VS, He Y, et al. Gene expression profiling of the cellular transcriptional network regulated by alpha/ beta interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein. J Virol 2003;77:6367-6375
18. Zhu Q, Guo JT, Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 2003;77:9204-9210
19. Hayashi J, Stoyanova R, Seeger C. The transcriptome of HCV replicon expressing cell lines in the presence of alpha interferon. Virology 2005;335:264-275
20. Keskinen P, Nyqvist M, Sareneva T, et al. Impaired antiviral response in human hepatoma cells. Virology 1999;263:364-375
21. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001;75:7059-7066
22. Bigger CB, Guerra B, Brasky KM, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004;78:13779-13792
23. DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996;14:457-460
24. Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005;129:2064-2075
25. Bieche I, Asselah T, Laurendeau I, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 2005;332:130-144
26. Helbig KJ, Lau DT, Semendric L, et al. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 2005;42:702-710
27. Alter HJ, Bradley DW. Non-A, non-B hepatitis unrelated to the hepatitis C virus (non-ABC). Semin Liver Dis 1995; 15:110-120
28. Dore GJ, Thomas DL. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005;25:18-32
29. Heller T, Rehermann B. Acute hepatitis C: a multifaceted disease. Semin Liver Dis 2005;25:7-17
30. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-1457
31. EASL International Consensus Conference on Hepatitis C Consensus statement. J Hepatol 1999;30:956-961
32. National Institutes of Health Consensus Development Conference Statement. Management of Hepatitis C: 2002. Hepatology 2002;36(suppl 1):S3-S21
33. Spada E, Mele A, Berton A, et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut 2004;53:1673-1681
34. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004;5:237-245
35. Congia M, Clemente MG, Dessi C, et al. HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders. Hepatology 1996;24:1338-1341
36. Tibbs C, Donaldson P, Underbill J, et al. Evidence that the HLA DQA1*03 allele confers protection from chronic HCV-infection in Northern European Caucasoids. Hepatology 1996;24:1342-1345
37. Alric L, Fort M, Izopet J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997;113: 1675-1681
38. Hohler T, Gerken G, Notghi A, et al. MHC class II genes influence the susceptibility to chronic active hepatitis C. J Hepatol 1997;27:259-264
39. Cramp ME, Carucci P, Underbill J, et al. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 1998;29:207-213
40. Zavaglia C, Martinetti M, Silini E, et al. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepatol 1998; 28:1-7
41. Kuzushita N, Hayashi N, Moribe T, et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 1998;27:240-244
42. Minton EJ, Smillie D, Neal KR, et al. Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. J Infect Dis 1998;178:39-44
43. Asti M, Martinetti M, Zavaglia C, et al. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. Hepatology 1999;29: 1272-1279
44. Mangia A, Gentile R, Cascavilla I, et al. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 1999;30:984-989
45. Thursz M, Yallop R, Goldin R, et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999;354:2119-2124
46. Barren S, Ryan E, Crowe J. Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J Hepatol 1999;30:979-983
47. Fanning LJ, Levis J, Kenny-Walsh E, et al. HLA class II genes determine the natural variance of hepatitis C viral load. Hepatology 2001;33:224-230
48. McKiernan SM, Hagan R, Curry M, et al. The MHC is a major determinant of viral status, but not fibrotic stage, in individuals infected with hepatitis C. Gastroenterology 2000;118:1124-1130
49. Thio CL, Gao X, Goedert JJ, et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002;76:4792-4797
50. McKiernan SM, Hagan R, Curry M, et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004;40:108-114
51. Cook DN, Beck MA, Coffman TM, et al. Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science 1995;269:1583-1585
52. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377
53. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-725
54. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-1862
55. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-1243
56. Michael NL, Chang G, Louie LG, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-340
57. Woitas RP, Ahlenstiel G, Iwan A, et al. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology 2002;122:1721-1728
58. Hellier S, Frodsham AJ, Hennig BJ, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003;38:1468-1476
59. Mangia A, Santoro R, D'agruma L, Andriulli A. HCV chronic infection and CCR5-delta32/delta32. Gastroenterology 2003;124:868-869
60. Zhang M, Goedert JJ, O'Brien TR. High frequency of CCR5-delta32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1. Gastroenterology 2003;124:867-868
61. Promrat K, McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003;124:352-360
62. Goulding C, McManus R, Murphy A, et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005;54:1157-1161
63. Wasmuth HE, Werth A, Mueller T, et al. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. Hepatology 2004;40:327-334
64. Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-betal genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002;36:271-277
65. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115:209-218
66. Friedman SL. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004;1:98-105
67. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-S56
68. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006;55:123-130
69. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002;122:366-375
70. Novo E, Marra F, Zamara E, et al. Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. Gut 2006;55:90-97
71. Neuman MG, Benhamou JP, Bourliere M, et al. Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. Cytokine 2002;17:108-117
72. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832
73. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(suppl 1):S35-S46
74. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340: 1228-1233
75. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000;32:91-96
76. Codes L, Asselah T, Cazals-Hatem D, et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of menopause and steatosis and the potential benefit of hormone replacement therapy. Gut 2006; September 27 (Epub ahead of print)
77. Czaja AJ, Carpenter H, Santrach PJ, Moore SB. DR human leukocyte antigens and disease severity in chronic hepatitis C. J Hepatol 1996;24:666-673
78. Haruna Y, Miyamoto T, Yasunami R, et al. Human leukocyte antigen DRB1 1302 protects against bile duct damage and portal lymphocyte infiltration in patients with chronic hepatitis C. J Hepatol 2000;32:837-842
79. Brandhagen DJ, Gross JB Jr, Poterucha JJ, et al. Human leukocyte antigen DR markers as predictors of progression to liver transplantation in patients with chronic hepatitis C. Am J Gastroenterol 2000;95:2056-2060
80. Tillmann HL, Chen DF, Trautwein C, et al. Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut 2001;48:714-718
81. Renou C, Halfon P, Pol S, et al. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut 2002;51:585-590
82. Pirisi M, Scott CA, Avellini C, et al. Iron deposition and progression of disease in chronic hepatitis C: role of interface hepatitis, portal inflammation, and HFE missense mutations. Am J Clin Pathol 2000;113:546-554
83. Erhardt A, Maschner-Olberg A, Mellenthin C, et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003;38:335-342
84. Hézode C, Cazeneuve C, Cou O, et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999;31:979-984
85. Knoll A, Kreuzpaintner B, Kreuzpaintner E, et al. Hemochromatosis mutation in hepatitis C: histopathology. Gastroenterology 1998;115:1307-1309
86. Smith BC, Gorve J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-1699
87. Thorburn D, Curry G, Spooner R, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002;50:248-252
88. Cui J, Eitzman DT, Westrick RJ, et al. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 2000;96:4222-4226
89. Papatheodoridis GV, Papakonstantinou E, Andrioti E, et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 2003;52:404-409
90. Wright M, Goldin R, Hellier S, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003;52:1206-1210
91. Marra F, DeFranco R, Grappone C, et al. Expression of the thrombin receptor in human liver: up-regulation during acute and chronic injury. Hepatology 1998;27:462-471
92. Kuzushita N, Hayashi N, Kanto T, et al. Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection. Gastroenterology 1999;116:1149-1154
93. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000;31:828-833
94. Sonzogni L, Silvestri L, De Silvestri A, et al. Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology 2002;36: 195-201
95. Wozniak MA, Itzhaki RF, Faragher EB, et al. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002;36:456-463
96. Strnad P, Lienau TC, Tao GZ, et al. Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology 2006;43:1354-1363
97. Adinolfi LE, Ingrosso D, Cesaro G, et al. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 2005;41:995-1003
98. Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006;130:1679-1687
99. Romero-Gomez M, Montes-Cano MA, Otero-Fernandez MA, et al. SLCIlAl promoter gene polymorphisms and fibrosis progression in chronic hepatitis C. Gut 2004;53: 446-450
100. Hamada H, Yatsuhashi H, Yano K, et al. Interleukin-10 promoter polymorphisms and liver fibrosis progression in patients with chronic hepatitis C in Japan. J Hepatol 2003;39:457-458
101. Muhlbauer M, Bosserhoff AK, Hartmann A, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003;125:1085-1093
102. Omary MB, Ku NO, Toivola DM. Keratins: guardians of the liver. Hepatology 2002;35:251-257
103. Goh PY, Tan YJ, Lim SP, et al. Cellular RNA helicase p68 relocalization and interaction with the hepatitis C virus (HCV) NS5B protein and the potential role of p68 in HCV RNA replication. J Virol 2004;78:5288-5298
104. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38: 1449-1457
105. Honda M, Kaneko S, Kawai H, et al. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001;120:955-966
106. Shackel NA, McGuinness PH, Abbott CA, et al. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol 2002;160:641-654
107. Smith MW, Yue ZN, Korth MJ, et al. Hepatitis C virus and liver disease global transcriptional profiling and identification of potential markers. Hepatology 2003;38: 1458-1467
108. Neuman MG, Benhamou JP, Malkiewicz IM, et al. Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat 2002; 9:134-140
109. Pockros PJ, Patel K, O'Brien C, et al. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. Hepatology 2003;37:1368-1374
110. Marcellin P, Boyer N, Gervais A, et al. Long term histologic improvement and disappearance of intra hepatic HCV RNA after alpha interferon therapy in patients with chronic hepatitis C. Ann Intern Med 1997;127:875-881
111. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with IFN-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965
112. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
113. Hadziyannis SJ, Sette H Jr, ,Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355
114. Matsushita M, Hijikata M, Ohta Y, Mishiro S. Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients. J Hepatol 1998;29:695-700
115. Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alpha. Hepatology 1999; 30:526-530
116. Yee LJ, Tang J, Gibson AW, et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001;33:708-712
117. Coelho-Borges S, Cheinquer H, Cheinquer N, et al. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload. Am J Gastroenterol 2002;97:1570-1572
118. Hennig BJ, Hellier S, Frodsham AJ, et al. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun 2002;3:359-367
119. Rosen HR, McHutchison JG, Conrad AJ, et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002;97:714-720
120. Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002;36:271-277
121. Woitas RP, Sippel M, Althausen EM, et al. Differential expansion of T-cell receptor variable beta subsets after antigenic stimulation in patients with different outcomes of hepatitis C infection. Immunology 2002;106:419-427
122. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-1444
123. Hayashida K, Daiba A, Sakai A, et al. Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2005;3:1253-1259
124. Ji X, Cheung R, Cooper S, et al. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 2003;37:610-621
125. Butera D, Marukian S, Iwamaye AE, et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005;106:1175-1182
126. Kingsmore SF. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev Drug Discov 2006;5:310-320
127. Jacobs JM, Diamond DL, Chan EY, et al. Proteome analysis of liver cells expressing a full-length hepatitis C virus replicon and biopsy specimens of posttransplantation liver from HCV-infected patients. J Virol 2005;79:7558-7569
128. Low TY, Leow CK, Salto-Tellez M, et al. A proteomic analysis of thioacetamide-induced hepatotoxicity and cirrhosis in rat livers. Proteomics 2004;4:3960-3974
129. Kristensen DB, Kawada N, Imamura K, et al. Proteome analysis of rat hepatic stellate cells. Hepatology 2000;32: 268-277
130. Xu XQ, Leow CK, Lu X, et al. Molecular classification of liver cirrhosis in a rat model by proteomics and bioinformatics. Proteomics 2004;4:3235-3245
131. Poon TC, Hui AY, Chan HL, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005;51:328-335
132. Paradis V, Asselah T, Dargere D, et al. Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. Gastroenterology 2006;130:2189-2197